|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
P2X7 receptor (P2X7R), encoded by the P2rx7 gene, is a trimeric ion channel activated by extracellular Adenosine triphosphate and is widely expressed in various types of tissues and tumors to regulate inflammation, cell proliferation, or death.
|
31276917 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Since the P2X7 receptor plays an important role in the maintenance of undifferentiated state of pluripotent cells, its importance on cell fate regulation in the tumor mass is suggested.
|
31813120 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we analyzed the different effect of P2X7 genetic deficiency versus its antagonism on response against P2X7-expressing implanted tumors.
|
30655604 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Factors released by glioma cells and P2X7R activation recruit microglia into the largely immunosuppressive tumour microenvironment where they have been demonstrated to contribute to either tumour proliferation or tumour suppression.
|
31031209 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Purinergic P2X7 Receptor: A Cation Channel Sensitive to Tumor Microenvironment.
|
30652649 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Consistent with data from in vitro experiments, systemic administration of P2X7 agonist induced tumor growth, metastasis and tumor-associated bone destruction in osteosarcoma-bearing nude mice, whereas a P2X7 antagonist reversed these effects.
|
30761524 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Role of the P2X7 receptor in tumor-associated inflammation.
|
30921559 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results showed that teniposide (TN) treatment significantly ameliorated bone nociception associated with tumor inoculation to a comparable extent with P2X7-specific inhibitor, BBG, in rat model.
|
28825192 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Preclinical studies in several tumour models have shown that P2X7R targeting is potentially a very effective anticancer treatment, and many pharmaceutical companies have now developed potent and selective small molecule inhibitors of P2X7R.
|
30006588 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The effects of purinergic receptor stimulation or agonism tend to produce inflammatory responses that may aid immune stimulation but may also provoke various immune suppression mechanisms, particularly in the tumor microenvironment.
|
30209547 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Bradykinin as pro-metastatic factor induced tumor proliferation that was significantly decreased by P2X7 receptor antagonists; however, the peptide did not enhance cell death nor P2X7A receptor-related pore activity, promoting neuroblastoma growth.
|
29867502 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High P2X7R expression significantly correlated with tumor size (P = .0177), Lymph node metastasis (P = .0128), and TNM stage (P = .0081).
|
28412208 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Knockdown of P2RX7-V3 expression significantly suppressed tumor growth in vitro and in vivo.
|
27468714 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The P2X7 receptor, which belongs to the ligand-gated ion channel receptor family, is involved in tumor development and metastasis.
|
25976617 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Receptor-analysis revealed a higher expression of P2X4 (p=0.03), P2X7 (p=0.001) and P2Y1 (p=0.003) in BAL cells of tumors with distant metastasis.
|
26505137 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Besides, peritumoral P2X7 density, which correlated with tumor size, venous invasion, and BCLC stage, was identified as an independent poor prognosticator for overall survival and recurrence-free survival.
|
25722111 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Of note, GL261 P2X7R silenced-bearing mice failed in respond to radiotherapy (8Gy) and GL261 WT-bearing mice, that constitutively express P2X7R, presented a significant reduction in tumor volume after radiotherapy, showing in vivo that functional P2X7R expression is essential for an efficient radiotherapy response in gliomas.
|
26358881 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
There is increasing awareness that many of the effects of extracellular ATP on tumor and inflammatory cells are mediated by the P2X7 receptor (P2X7R).
|
24651438 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Several recent studies have shown a crucial role of P2X7R in tumour cell growth, angiogenesis and invasiveness.
|
25226385 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The ATP-gated P2X7 has been shown to play an important role in invasiveness and metastasis of some tumors.
|
25486274 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results suggest that the efficacy of BBG in inhibiting tumor growth is primarily mediated by direct actions of the compound on P2X7R in glioma cells and that pharmacological inhibition of this purinergic receptor might serve as a strategy to slow the progression of brain tumors.
|
21157381 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The extracellular ATP-gated cation channel, P2X7 receptor, has an emerging role in neoplasia, however progress in the field is limited by a lack of malignant cell lines expressing this receptor.
|
20647033 |
2010 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We investigated tumour DNA in 170 patients with CLL using PCR-RFLP analysis with HhaI restriction enzyme cleavage to screen for the polymorphism in the P2X7 receptor gene.
|
12493261 |
2002 |